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Abstract
Background: Current anti-malarial drugs have been selected on the basis of their activity against the symptom-causing
asexual blood stage of the parasite. Which of these drugs also target gametocytes, in the sexual stage responsible for
disease transmission, remains unknown. Blocking transmission is one of the main strategies in the eradication agenda and
requires the identification of new molecules that are active against gametocytes. However, to date, the main limitation for
measuring the effect of molecules against mature gametocytes on a large scale is the lack of a standardized and reliable
method. Here we provide an efficient method to produce and purify mature gametocytes in vitro. Based on this new
procedure, we developed a robust, affordable, and sensitive ATP bioluminescence-based assay. We then assessed the
activity of 17 gold-standard anti-malarial drugs on Plasmodium late stage gametocytes.
Methods and Findings: Difficulties in producing large amounts of gametocytes have limited progress in the development
of malaria transmission blocking assays. We improved the method established by Ifediba and Vanderberg to obtain viable,
mature gametocytes en masse, whatever the strain used. We designed an assay to determine the activity of antimalarial
drugs based on the intracellular ATP content of purified stage IV–V gametocytes after 48 h of drug exposure in 96/384-well
microplates. Measurements of drug activity on asexual stages and cytotoxicity on HepG2 cells were also obtained to
estimate the specificity of the active drugs.
Conclusions: The work described here represents another significant step towards determination of the activity of new
molecules on mature gametocytes of any strain with an automated assay suitable for medium/high-throughput screening.
Considering that the biology of the forms involved in the sexual and asexual stages is very different, a screen of our 2
million-compound library may allow us to discover novel anti-malarial drugs to target gametocyte-specific metabolic
pathways.
Citation: Lelie`vre J, Almela MJ, Lozano S, Miguel C, Franco V, et al. (2012) Activity of Clinically Relevant Antimalarial Drugs on Plasmodium falciparum Mature
Gametocytes in an ATP Bioluminescence ‘‘Transmission Blocking’’ Assay. PLoS ONE 7(4): e35019. doi:10.1371/journal.pone.0035019
Editor: Ross Frederick Waller, University of Melbourne, Australia
Received October 27, 2011; Accepted March 8, 2012; Published April 13, 2012
Copyright:  2012 Lelie`vre et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: JL SL MJA EH CM are employees of GlaxoSmithKline (GSK) and
work was funded by GSK under a general research program. DL is employee of Medicines for Malaria Venture (MMV). This does not alter the authors’ adherence to
all the PLoS ONE policies on sharing data and materials. Neither GSK nor MMV have influenced or biased the content of this work.
* E-mail: Joel.l.lelievre@gsk.com (JL); esperanza.a.herreros@gsk.com (EH)
. These authors contributed equally to this work.
¤ Current address: Centro de Biologı´a Molecular (UAM-CSIC), Campus de la Universidad Auto´noma de Madrid, Madrid, Spain
Introduction
Recent years have witnessed renewed impetus for malaria
control but this disease is still leading to nearly 1 million deaths
annually. This is why the Malaria Eradication Research Agenda
(malERA, http://malera.tropika.net) initiative, created in 2007,
re-established the long-term goal of malaria eradication. Spread
and maintenance of the malaria parasites rely on their transmis-
sion between humans and Anopheles. Attempts at eradication
should therefore include transmission-blocking approaches aiming
at identification of therapies capable of eliminating Plasmodium
gametocytes, the sexual forms of the parasite. To test potential
anti-gametocyte drugs, both an improved gametocyte production
method and a reliable assay to assess activity of compounds against
mature gametocytes are required.
The biology of gametocytes is complex and consists of five
morphologically identifiable stages: stages I to IV (immature
gametocytes) sequestered into human tissues; and stage V, the
infectious sexual form that circulates in the blood-stream. Despite
some attempts to gain insights into the biology of the parasite’s
gametocytes and to identify potential drug targets within their
proteomes [1], identification of new molecules blocking the
production of these forms relied mainly on phenotypic assays
and recently on a small number of novel assays using ATP
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detection [2], flow cytometry [3], stage-specific markers such as
Pfs16 [4,5] or both of the latter two methods [6].
Moreover, the renewed interest in parasite transmission has
highlighted a crucial need for additional tools. Difficulties in
producing large amounts of this form have limited research
progress in the development of blocking transmission assays. Using
the method of Trager and Jensen, Smalley was the first to attempt
to obtain sexual forms of the parasite, but these gametocytes were
not, or were rarely and unpredictably functional, even when they
were allowed to develop for a longer time [7]. In 1981, Ifediba and
Vanderberg improved the method by adding hypoxanthine to the
culture medium and obtained mature P. falciparum gametocytes
[8]. It later became possible to remove the asexual forms in most
gametocyte production protocols by introducing N-acetyl-D-
glucosamine (GLcNA), a sugar that completely blocks invasion
of the erythrocyte by this parasite but does not affect gametocyte
maturation [9]. More recently, Mann found that addition of
bistratene A, a protein kinase C inhibitor, also inhibited merozoite
invasion and reportedly induced gametocytogenesis [10]. More-
over, Fivelman et al [11] established a useful but complex protocol
to obtain gametocytes reaching different maturation stages. All of
these methods have a low production rate and suffer from costs
and reproducibility problems because culture medium is currently
supplemented with human serum in different proportions.
Currently, we lack effective activity assays against late stage
gametocytes. The gold standard test relies on dose-response
measurement by manual microscopic counting of the number of
gametocytes after drug exposure at different concentrations. This
method is time-consuming and subject to human error. Flow
cytometry has been proposed to assess the in vitro gametocytocidal
activities of potential anti-plasmodial drugs [3] but each well has to
be processed on costly equipment. Whilst an improvement on the
light microscopy method, the use of cytometry does not allow for
large-scale assessment of compound activity on late-stage game-
tocytes. Another promising assay, which has recently been
developed [2], is based on detection of fluorescence of reduced
alamar blue. Nevertheless, several important drawbacks to its
routine use have been reported [12] such as the amount of
gametocytes required, and the targeted stage which is not confined
to mature gametocytes. The ATP bioluminescent assay remains a
gold standard to explore parasite viability. ATP plays a central role
in energy exchanges in biological systems (both eukaryotic and
prokaryotic), serves as the main donor of free energy, and is
produced in all metabolically active cells. This parameter is
currently used as a tool to assess the functional integrity of living
cells. Injury and death result in a rapid decrease in cytoplasmic
ATP, [13] which therefore provides a reliable platform to test the
effect of small molecules on the ability of gametocytes to develop.
An assay based on ATP has in fact been published recently.
However, methodological flaws can be noted; a crucial one is the
use of frozen gametocytes [14].
We report an innovative solution to produce and purify mature
(stage IV–V) gametocytes and to develop and validate a method
based on bioluminescence-mediated detection of ATP as the
preferred measure of gametocyte viability. This assay has been
validated successfully and for the first time provides extensive
activity data of 17 clinically relevant antimalarial drugs.
Results
Gametocyte production protocol
Capitalizing on previous studies, we developed a method which
overcomes some significant constraints. We started to use lipid-
rich bovine serum albumin concentrate (AlbuMAX II) instead of
the standard supplement, human serum. AlbuMAX is much
cheaper and avoids variability between the different serum batches
and donors, thus increasing the reliability of the assay. We also
kept adding hypoxanthine to the basal medium throughout the
process and added N-acetyl-D-glucosamine and bistratene A
during the last phase of gametocyte differentiation to obtain
approximately 1–2% gametocytemia (stage IV and V) between
day 15 and day 18.
Under these conditions, different strains of P. falciparum (3D7A,
W2, NF54, Dd2 and 3D7HT-GFP) were tested to determine
which one was the most appropriate. Differences in gametocyte
production were seen among these strains. The P. falciparum
3D7HT-GFP strain [15], that constitutively expresses green
fluorescent protein (GFP), showed the highest sexual differentia-
tion ratio and the greatest ability to mature and was therefore used
to set up the assay. The gametocytogenesis profile of the 3D7HT-
GFP strain is shown in Figure 1.
Purification process
Our gametocyte culture is composed of 1–2% mature
gametocytes but also 98–99% red blood cells (RBCs), which
contain a significant intracellular ATP concentration that
interferes with the readout. It was therefore necessary for RBCs
to be removed from the culture. Stage IV–V gametocyte cultures
were enriched on a Nycoprep cushion, based on density
differences between gametocytes and RBCs. Most RBCs were
depleted, but an accurate quality control of samples showed that
an unacceptable number remained. An additional purification
step, consisting of magnetic column separation, was thus
performed. The ability of all Plasmodium erythrocytic species to
degrade hemoglobin (a Fe(II) diamagnetic complex) to hemozoin
(a Fe(III) paramagnetic complex) [16] was used, making
discrimination between retained gametocytes and eluted RBC
possible when the magnetic field was applied. We thus managed to
obtain a culture containing more than 70% stage IV–V
gametocytes (Fig. 2). We were then concerned by the viability of
gametocytes after this two-step purification. Intracellular ATP
Figure 1. Kinetics of parasitaemia (asexual stages only, black
dots) and gametocytaemia (stages 1–5; black squares) by
microscopic observation, represented as a percentage of total
erythrocytes. The number of asexual forms increased up to maximum
parasitaemia on day 11. From that time onwards, a rapid decrease
occurred leading to a parasitaemia (asexual stages) close to zero on day
17. Sexual forms were first detected on day 7, and gametocytaemia
reached a peak of 1.69% on day 13. The gametocytes, initially in early
forms, developed into mature stages reaching stages IV and V from day
15 to 20. After day 15, more than 70% of the gametocytes are in stage
IV–V.
doi:10.1371/journal.pone.0035019.g001
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level, morphology, internal motility and response to exflagellation
stimuli were therefore all checked (data in annex) at T= 0 h and
T=48 h, and the results showed that our purification approach
did not significantly affect either viability or exflagellation of
gametocytes throughout the purification procedure.
Assay development and validation
Following successful mass production of viable gametocytes, an
assay for large-scale testing of the activity of compounds against
stage IV–V gametocytes, by measuring ATP levels after drug
exposure, was developed. Gametocytes ATP intracellular levels
were measured by the luciferin-luciferase methodology.
Firstly, to assess the robustness and the quality of the ATP
bioluminescence assay we calculated the Z9-factor, the screening
window coefficient (calculated with the control data) [17]. Values
between 0.5 and 1.0 indicate excellent assay quality. The Z9-factor
for the assay (6 standard deviation) was 0.68 (60.02). To
determine whether ATP quantification provided a readout that
was directly proportional to the number of viable parasites, we
compared microscopy counts with ATP levels. This is important to
confirm the reliability of the assay. A high degree of correlation
was observed (R2 = 0.99) as shown in Figure 3.
Then, to validate the assay, 6 common anti-plasmodial drugs
such as epoxomicin, dihydroartemisinin, artesunate, primaquine,
chloroquine and methylene blue were tested. Dose-response
curves and IC50 values determined by quantification of the intra
cellular ATP were compared to those obtained in parallel using
the standard method of microscopic enumeration of gametocytes
on stained smears after drug exposure. Cytotoxicity studies were
also carried out to investigate the corresponding selectivity ratio
(activity in HepG2 cells versus activity against P. falciparum
gametocytes)
The first compound evaluated, the proteasome inhibitor
epoxomicin, is known to have a very potent effect on gametocytes
[2]. In the present study, it also exhibited a very high activity in
both the ATP bioluminescence assay (0.42 nM) and microscop-
ically (5.2 nM). Nevertheless, IC50 values (3 nM) in HepG2 cells
were in the same range, suggesting a total lack of selectivity.
Inhibition of proteasome activity has a toxic effect on the parasite,
but this function is also essential in mammalian cells and,
considering the difference of cytotoxicity exhibited by epoxomicin
on the HepG2 cell line and on mouse 3T3 or human A549 cells
[18], its use may have to be reconsidered.
The two artemisinin derivatives used in our study, dihydroarte-
misinin (DHA) and artesunate, had no particular activity against
mature gametocytes with IC50 values of 3.56 mM and 10.83 mM
respectively. Activity of artemisinins against these forms is still
controversial as very few data have been reported. The effect of
artesunate was described in only two studies that found IC50 values
of 108 nM [19] and 0.1 ng/mL [20]. A single article, describing a
new flow cytometry assay [3] , demonstrated an IC50 of 1 mM for
artemisinin on late gametocytes and its metabolite, DHA, was
found to inhibit gametocytes by 70.4% at 1 mM [2]. It is well
known that treatment of Plasmodium with artemisinin derivatives is
associated with lower rates of gametocyte carriage [21,22] but
there is a huge gap in in vitro knowledge and additional work is
required. Interestingly, the two artemisinin derivatives in the
present study showed a high selectivity for the target in asexual
stages as IC50 values obtained in HepG2 cells exceeded 50 mM.
Primaquine has been reported to selectively destroy the inner
structure of P.falciparum mitochondria. The mechanism by which
primaquine causes its effects on mitochondria remains unclear. It
is assumed that primaquine activity depends to a large extent on
the formation of metabolites which are more active than the
parent compound [23]. This 8-aminoquinoline has long been
known to reduce the prevalence of circulating gametocytes in the
peripheral bloodstream of parasitemic individuals and to prevent
exflagellation among gametocytes present in the test [24,25]. The
IC50 on late gametocytes (20.9 mM) and asexual forms (.10 mM)
described in this study are in accordance with current literature.
Due to the absence of the active metabolites involved in its
mechanism of action, primaquine remains inactive in vitro. The
related 4-aminoquinolines, including chloroquine, affect P.
falciparum immature gametocytes but not mature gametocytes
[26]. Chloroquine kills the Plasmodium parasite by inhibiting
hemozoin formation and glutathione degradation. Absence of
these metabolic reactions at stages IV and V would account for the
inactivity of chloroquine reported by Smalley et al. [26] The IC50
of chloroquine observed with our ATP bioluminescence assay
(23.47 mM) agreed with the values reported in the literature.
Methylene blue (MB) has recently been reconsidered as a useful
antimalarial drug [4] and has been explored in combination with
CQ and artemisinin derivatives [27]. MB was identified as a
specific inhibitor of P. falciparum glutathione reductase, and blocks
Figure 2. Giemsa-stained culture of gametocytes on day 15
after both Nycoprep and magnetic purification steps, (10006).
doi:10.1371/journal.pone.0035019.g002
Figure 3. ATP level per gametocyte number (R2 =0.99) counted
with the luminometer after serial dilution. Gametocytes were
counted using a Neubauer chamber. Each point represents mean values
of 3 replicates 6 SD.
doi:10.1371/journal.pone.0035019.g003
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heme polymerization within the food vacuole, is active against all
asexual blood stages. Promising data have been reported in clinical
trials [28] and, to date, only one publication has shown the in vitro
activity of MB in mature gametocytes [4]. Our study evaluated for
the first time the IC50 of MB on stage IV–V gametocytes
(0.49 mM) and the IC50 on the HepG2 cell line (6.52 mM), and
found good activity but quite high cytotoxicity.
As mentioned earlier, it was essential to determine the activity
on mature gametocytes using the gold standard microscopy-based
parasite enumeration to validate the assay. As an example, the
dose-response curves obtained for both artesunate and methylene
blue were represented in Figure 4 and all the IC50 results are
summarized in Table 1. Microscopy examination showed IC50
values comparable to those obtained with the ATP biolumines-
cence assay in all cases. Differences were expected because one of
the drawbacks of the microscopic method is that all parasites are
counted, including dead parasites that represent false positives.
Even with this shift, the active/inactive profile observed in the
dose-response curves calculated from microscopic observations
supported the results found with the ATP bioluminescence assay
and thus validated this technique.
From validation to test
After validation had been performed and based on the
differences in mechanisms of action, 10 other drugs currently in
use or in clinical development were tested against mature
gametocytes using the ATP bioluminescence assay.
The activity against asexual stages was also determined (Table 2)
with the reference strain line 3D7A and the 3D7HT-GFP strain to
confirm that they both have the same behavior. The activity
against mature gametocytes was done using the 3D7HT-GFP
strain. Finally, cytotoxicity in the human cell line HepG2 was
assessed.
Among the 10 newly tested compounds, quinine and meflo-
quine, were first investigated. As with other quinoline anti-malarial
drugs, the mechanism of action of quinine has not been fully
elucidated. The most widely accepted hypothesis about quinine
action is based on data for the closely related drug, mefloquine
[29,30]. These data suggest that its main mode of action may be to
inhibit hemoglobin ingestion by blocking the endocytotic process
[31]. Although they are active against asexual blood stages of
chloroquine-resistant (CQR) and sensitive (CQS) P. falciparum
strains [32,33,34], neither quinine (IC50 above 50 mM) nor
mefloquine (IC50 = 4.7 mM) showed good activity on late game-
tocytes. Moreover, the selectivity ratio of mefloquine (2.34) was
quite narrow (IC50 of 11 mM in HepG2 cells versus IC50 of
4.9 mM in gametocytes)
Several of the compounds that act on hemoglobin metabolism
were also evaluated; halofantrine, lumefantrine and isoquine. The
exact mechanism by which halofantrine and lumefantrine exert
their anti-malarial effect is not well defined. However, available
data suggests that halofantrine binds to plasmepsin, a hemoglobin-
degrading enzyme and to haematin in vitro and lumefantrine
inhibits the formation of ß-haematin by forming a complex with
haemin. Isoquine, on the other hand, was developed as a
potentially safer alternative to amodiaquine, an effective but toxic
substitute of chloroquine. Halofantrine, isoquine and lumefantrine
(used in the ‘‘co-artemether’’ combination) are active on asexual
blood stages of CQR strains [32,35,36] but no significant activity
on mature gametocytes was detected (IC50 = 6.7; 28.5 and
.50 mM, respectively) [37]. Lumefantrine and halofantrine were
less cytotoxic than isoquine in vitro with an IC50 higher than 50 mM
for both, compared to 17.07 mM for isoquine.
Pyronaridine-artesunate is a promising new artemisinin-based
combination therapy for the treatment of uncomplicated falciparum
malaria. Pyronaridine is also thought to inhibit parasite develop-
ment because of its ability to inhibit b-haematin formation. It has
been shown to have a high in vitro activity against chloroquine-
sensitive and chloroquine-resistant strains of P. falciparum [38].
Moreover, some activity against gametocytes has been reported
[39] but what was probably seen was an effect on young
gametocytes because the IC50 for mature gametocytes was
approximately 3.25 mM with the ATP bioluminescence assay.
The antifolate family is an important group of antimalarials of
which pyrimethamine is a crucial member. The compound was
introduced here as an internal control as the strain P. falciparum
3D7HT-GFP contains a selection cassette giving resistance to
drugs acting on DHFR. The drug, as expected, did not have any
effect on mature gametocytes of this resistant line.
It should be noted that atovaquone, which is often used today in
the atovaquone-proguanil combination (Malarone), showed very
strong in vitro activity against asexual erythrocytic P. falciparum
cultures (IC50 = 1.8 nM) but had no activity against gametocytes
according to our ATP assay (IC50 = 16.10 mM) and previous
reports [19]. It has been shown that atovaquone does inhibit
transmission [37,40] but has no effect on mature gametocytes [41].
No cytotoxic effects were detected at the maximum solubility of
atovaquone in culture media.
Figure 4. Comparison of the dose-response curves of artesunate and methylene blue obtained with the ATP bioluminescence assay
(black dots) or by microscopic counting (open circles). Each point represents mean values of 4 replicates 6 SD.
doi:10.1371/journal.pone.0035019.g004
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Use of antibiotics was also investigated. Cycloheximide is an
inhibitor of protein biosynthesis in eukaryotic organisms that
interferes with the translocation step in protein synthesis.
Experimental evidence of antimalarial activity is available for this
drug [42] but it showed low activity when tested on stage IV–V
gametocytes (IC50 = 6.23 mM), as described previously [43].
Asexual forms of the parasite may also be killed by targeting the
apicoplast. Azithromycin is a macrolide antibiotic derived from
erythromycin. It is not yet licensed for use as an antimalarial agent
but has shown promising activity against P. falciparum in vitro [44].
This drug appeared to have some effect upon parasite develop-
ment in the mosquito stage [45] but had no effect upon mature
gametocytes, in the present study (IC50 = 28.45 mM) and in other
experiments [46].
Discussion
The eradication of malaria will remain an elusive goal unless
drugs are found that either massively reduce or, even better, fully
inhibit disease transmission. The lack of tools to assess the activity
of compounds against the key actors, mature gametocytes, is the
real problem at present. Some attempts have been made
[2,3,4,14], but published methods are still labor-intensive, costly
and/or complex, making development of such a large-scale
screening difficult.
Table 1. Comparison of the activity against mature
gametocytes (IC50) using either the ATP bioluminescence
assay or the microscopical enumeration.
Compounds
IC50 gametocytes (mM)
Microscopy examination
IC50 gametocytes (mM)
ATP method
Chloroquine 28.4 23.47
Artesunate 2.26 10.83
Methylene blue 0.76 0.49
Primaquine 87.9 20.9
Dihydroartemisinin 2.47 3.56
Epoxomicin 0.0052 0.00042
doi:10.1371/journal.pone.0035019.t001
Table 2. In vitro activity of the compounds against asexual stages, mature gametocytes and assessment of cytotoxicity in the
HepG2 cell line.
Compounds IC50 (mM)
Activity against asexual
forms (3D7A)
Activity against asexual forms
(3D7HT-GFP)
Activity against mature
gametocytes IV–V Cytotoxicity
Quinolines
Chloroquine 0.00660.0002 0.00760.002 23.4762.66 51.8467.86
Primaquine .10 .10 20.9064.65 .50
Isoquine 0.00960.0016 0.004460.0032 28.562.12 17.0766.3
Pyronaridine 0.004560.0015 0.0008060.0001 3.2560.92 5.9560.92
Artemisinin Endoperoxides
Artesunate 0.03760.025 0.05460.03 10.8363.7 .50
Dihydroartemisinin 0.002860.0007 0.01360.003 3.5660.95 .50
Amino alcohols
Quinine 0.06660.018 0.10660.040 .50 .50
Mefloquine 0.02660.017 0.02860.0014 4.7062.10 1160.26
Lumefantrine 0.003260.00014 0.0016560.00007 .50 .50
Halofantrine 0.001160.0005 0.001260.0005 6.7060.42 .50
DHFR-TS inhibitors
Pyrimethamine 0.002560.0009 33.6666.72* .50 .50
Hydroxy-naphthoquinones
Atovaquone 0.000760.0004 0.001860.0002 16.1062.12 .40a
Proteasome inhibitors
Epoxomicin 0.00860.001 0.009860.0017 0.0004260.00011 0.00360.0005
Dyes
Methylene blue 0.01160.008 0.01060.0018 0.4960.16 6.5261.31
Protein synthesis inhbitors
Azythromycin .10 .10 28.4560.64 .50
Cycloheximide 0.19860.0017 0.19460.0077 6.2362.46 2.9560.35
Inhibition of uptake of a radiolabeled nucleic acid precursor by the parasites served as the indicator of antimalarial activity against asexual stages while the activity on
mature gametocytes was determined with the ATP bioluminescence assay. Finally, cytotoxicity was assessed using the short-term resazurin-based reductase assay. All
the results are expressed as the average value of the IC50 6 standard deviation (3–6 independent experiments).
alimit of solubility.
*resistance to pyrimethamine due to a selection cassette in the episome (containing the GFP gene).
doi:10.1371/journal.pone.0035019.t002
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Compared to previous methods that assessed the activity of new
chemical entities against mature gametocytes, the technique that
we have devised has several advantages. This ATP biolumines-
cence assay is highly sensitive; the luminometric technique is able
to detect a low number of cells (16104 per well in a 384-well plate)
even if these cells display a low metabolic activity. This method
measures the whole well in the microtiter plate, representative of a
population of parasites. When samples are analyzed by micros-
copy, only an aliquot is taken from the well to prepare a smear and
only some fields are counted at random. In addition, our
methodology does not rely on operator expertise and is therefore
not subject to person-to-person variability. Uncertainty about the
viability of parasites when counting is overcome by this new
method as only metabolically active parasites are detected.
Reading of luminescence is fast, requiring a minimum number
of handling steps and providing results within 15 minutes. The
plate is read instantaneously and there is no need for time-
consuming incubation, as required by other techniques (e.g.
alamar blue). An important advantage is that the method can be
used to directly evaluate the activity on any parasite strain or
clinical isolates as it does not require the use of any parasite line
transformed with reporter genes. Moreover, this system is
amenable to adaptation to 384-well plates allowing the testing of
a higher number of compounds than with traditional manual
counting or the flow cytometry technique.
In summary, the work described here provides, for the first time,
data on the activity of all clinically relevant antimalarial drugs
against mature gametocytes and represents a significant step
towards development of a high-content method suitable for high-
throughput screening of new molecules at these stages. Consid-
ering that the biology of the forms involved in the sexual and
asexual stages is very different, a large-scale high-throughput
screen using the GlaxoSmithKline 2 million-compound library
may allow us to discover innovative anti-malarial drugs to target
novel transmission-specific metabolic pathways.
Methods
Parasites and Cultures
Three strains of Plasmodium falciparum, W2-Indochina (MR4,
MRA-157), 3D7A (MR4, MRA-151) and the 3D7HT-GFP strain
[15], kindly provided by Robert E. Sinden, were cultured using a
method modified from that of Trager and Jensen [47] in a 5%
CO2/5% O2 atmosphere at 37uC [48].
Gametocytogenesis
Gametocyte cultures of each strain were initiated as described
by Ifediba and Vanderberg [8], but with the following minor
variations: On day 0, cultures were synchronized at the ring stage
by lysis of the flask pellet with 5 volumes of 5% sorbitol for 10 min
at 37uC. Cultures were then initiated at 0.2% parasitaemia and
12% hematocrit in a 10 mL volume. The culture was first
incubated in RPMI 1640 (Gibco) supplemented with hypoxan-
thine (Sigma-Aldrich), sodium bicarbonate (Sigma-Aldrich) and
15% AlbuMAX II solution. On day 8, the volume was doubled
and the concentration of AlbuMAX was reduced to 10%. Finally,
on day 12, cultures were treated with 50 mM N-acetyl-D-
glucosamine (GLcNA, Sigma-Aldrich) and 50 ng/mL of bistratene
A for 3–5 days to remove asexual forms. Medium was changed
daily throughout the process. To assess gametocytogenesis curves
(Fig. 1), the percentage of asexual forms and gametocytes were
counted on Giemsa-stained smears.
Purification
On day 15 (Fig. 1), the majority of the gametocytes were stage
IV–V. At this point, parasites were concentrated with Nyco-
PrepTM 1.077 cushions (Axis-Shield). The culture pellet was
washed, resuspended in 10 mL of medium and placed slowly onto
5 mL of Nycoprep cushion in a 15 mL Falcon tube. The tube was
centrifuged at 800 g for 20 minutes. The band was collected,
washed, and spun down and the pellet was resuspended in 5 mL of
medium. During the entire procedure the gametocytes were
maintained at 37uC. A Giemsa-stained smear was prepared at this
point. The solution containing the gametocytes was then loaded
onto a LS-Column (Miltenyi Biotech) to carry out the second
purification step using a VarioMACS magnetic separator (Miltenyi
Biotech). The column was washed with 5 mL of medium to elute
the remaining RBCs and, finally, gametocytes were immediately
flushed out by removing the column from the holder, adding 5 mL
of medium, and firmly applying the plunger supplied with the
column. On average, 2.5 to 10 million gametocytes were obtained
from a 25 cm2 culture flask.
IC50 assays
Compounds used for the validation included dihydroartemisinin
(Sigma-Aldrich), artesunate (Apin Chemicals Limited), epoxomicin
(Sigma-Aldrich), primaquine (Sigma-Aldrich), methylene blue
(Sigma-Aldrich) and chloroquine (Sigma-Aldrich). The first four
compounds were dissolved in DMSO, while chloroquine and
methylene blue were dissolved in water.
ATP bioluminescence assay. Once purified, gametocytes
were counted using a Neubauer chamber. Gametocytes (56104
gametocytes per well) were transferred to a 96-well plate in a final
volume of 100 mL, and dilutions of each drug were added (final
DMSO concentration 0.5%). Plates were incubated (at 37uC in a
5% CO2 humidified incubator) for 48 h. The ATP level of each
well was determined using the BacTiter-GloTM reagent (Promega)
according to manufacturer’s recommendations. The BacTiter-
GloTM assay generates a ‘‘glow-type’’ luminescent signal produced
by the luciferase reaction, which consists of mono-oxygenation of
luciferin catalyzed by luciferase in the presence of Mg2+, ATP,
and molecular oxygen.
Microscopic measurement of IC50 values. IC50 values
were determined after 48 h of incubation with different dilutions
of the drugs. 100 ml of the culture (day 15, HT 6%) were plated in
each well with the appropriate dilution of drug. 48 h after, 10 ml of
each well was used to prepare a thin blood film and stain it with
Giemsa. The number of gametocytes per 10,000–15,000 RBCs
were counted and compared to the control (no drug, 0.5%
DMSO).
In vitro antiplasmodial activity on asexual stages. IC50
values were measured as previously reported [49] but all of the
tests were done with serum-free cultures (using AlbuMAX II)
Cytotoxicity
Cell line. HepG2, a human caucasian hepatocellular
carcinoma, was supplied by ECACC (ref. 85011430).
Routine culture. Cells were grown and maintained in
EMEM (Sigma-Aldrich) supplemented with 2 mM L-glutamine
(Sigma-Aldrich) and 10% fetal calf serum (Perbio). Cultures were
maintained at 37uC in a humidified incubator containing 5%
CO2, 95% air and passages were routinely made upon reaching
80% to 90% confluence. For cytotoxicity experiments, cells were
seeded onto 96-well clear bottom black plates coated with type I
collagen (Biocoat, Becton Dickinson) at a cell density of 10000
cells/well.
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Measurement of cytotoxicity. To determine cytotoxic
effects, represented by the IC50 value (the concentration of drug
that reduces cell viability by 50%), cells were exposed to serial
dilutions of test compounds for 48 h at 37uC. The culture medium
was as described above, but supplemented with 5% fetal calf
serum. Following the 48 h exposure period, a 0.004% resazurin
solution was prepared by adding 60 mL of Dulbecco’s PBS to each
resazurin tablet (VWR International). The tablet was allowed to
dissolve by placing the container in a bath maintained at 37uC,
protected from light, for approximately 30 minutes. Medium was
removed and 200 mL of fresh culture medium and 50 mL of
resazurin solution were added to each well. Plates were incubated
for a further 1 K hours. Cytotoxicity is indicated by decreased
reduction of resazurin to its fluorescent product resorufin. The
fluorescence was stabilized at room temperature for 15 minutes
protected from light. Fluorescence was measured using a
fluorescence plate reader (Victor V, Perkin Elmer) at an
excitation wavelength of 515 nm and an emission wavelength of
590 nm. Percentages of inhibition were calculated relative to the
control wells.
Selectivity ratio. We defined the selectivity ratio as the IC50
value in HepG2 cells/IC50 value in P.falciparum. For a late lead or
a preclinical candidate, a differential sensitivity between host and
parasite at cellular level higher than 100-fold is considered
acceptable.
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